Free Interactive Tool · Updated 2026

Rare Disease Licensing Deal Calculator —
benchmark your deal in 60 seconds

Phase 2 rare disease deals median ~$60M upfront, ~$900M total. Gene therapies (DMD, SMA, hemophilia) command 3–5x multiples — $300M+ upfronts not uncommon. Built on 1,900+ verified biopharma transactions across 12 therapeutic areas.

Run free rare disease benchmark Try Pro free for 7 days

1,900+ verified deals12 therapeutic areasSourced from SEC EDGAR + FTC filings

Rare Disease deal benchmarks at a glance

Median deal terms for rare disease licensing transactions, by development phase. Data current as of 2026.

Phase	Median Upfront	Median Total Value	Median Royalty (Tiered)
Preclinical	$18M	$460M	4–8%
Phase 1	$45M	$780M	5–10%
Phase 2	$105M	$1.4B	7–14%
Phase 3	$290M	$3.1B	10–18%

Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.

Recent comparable deals

Pfizer–Biohaven ($11.6B, migraine + rare neuro)
Novartis–The Medicines Company ($9.7B inclisiran)
BioMarin–Roctavian (gene therapy)

Why Rare Disease is priced this way

Rare disease consistently commands premium economics: orphan designation, accelerated review pathways, and high price-per-patient ($200K–$3M annual). M&A multiples often exceed in-licensing.

Try it live

Run a Rare Disease deal scenario

Pick your phase, modality, and indication. Get instant benchmark ranges — no signup needed to start.

Quick Benchmark

Live data from 1,900+ deals. Select your parameters:

Therapeutic Area

Phase

Modality

$375M

Upfront

$2.1B

Total Deal Value

7.5–15%

Base Royalty

$182M–$569M

Upfront Range

Full Analysis with 15+ ParametersIncludes rNPV, Monte Carlo, comparable deals, and negotiation playbook

Run a full deal analysis

Rare Disease licensing — frequently asked

What is the median upfront payment for a Rare Disease licensing deal?

Across 1,900+ verified biopharma transactions, median Rare Disease upfront payments range from $18M (preclinical) to $290M (Phase 3). Phase 2 rare disease deals median ~$60M upfront, ~$900M total. Gene therapies (DMD, SMA, hemophilia) command 3–5x multiples — $300M+ upfronts not uncommon.

How are Rare Disease deal milestones structured?

Typical Rare Disease deals split milestones into development (35–45% of total), regulatory (10–20%), and commercial (40–55%). Phase 2 Rare Disease deals carry ~$300–700M in development + regulatory milestones, with sales milestones tied to net sales thresholds ($500M, $1B, $2B+ tiers).

What royalty rates are typical for Rare Disease licensing?

Tiered royalty rates for Rare Disease typically run 8–18% on net sales, structured in 3–5 sales-volume tiers. First-in-class Rare Disease assets command upper-range tiers (15–22% peak); follow-on compounds often see compressed 5–12% structures.

Is there a free Rare Disease deal calculator?

Yes — the Ambrosia Benchmarker Rare Disease calculator runs deal valuations free using 1,900+ verified transactions as the comp set. Pro tier ($299/mo, free 7-day trial) adds Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and full PDF reports.

How does Rare Disease licensing compare to other therapeutic areas?

Rare disease consistently commands premium economics: orphan designation, accelerated review pathways, and high price-per-patient ($200K–$3M annual). M&A multiples often exceed in-licensing.

7-Day Free Trial · No Promo Code

Run unlimited rare disease deals — Pro.

Monte Carlo sensitivity, partner matching across 850+ companies, scenario comparison (Bear/Base/Bull rNPV), and board-ready PDF reports. Free for 7 days. Cancel anytime.

Start 7-day free trial Or keep using free calculator

Then $299/month · No charge during trial · Cancel anytime

More therapeutic-area calculators

Oncology Neurology Immunology Metabolic / Obesity Cardiovascular Infectious Disease Ophthalmology Women's Health Hematology Dermatology Gastroenterology

Rare Disease Licensing Deal Calculator —
benchmark your deal in 60 seconds

1,900+ verified deals12 therapeutic areasSourced from SEC EDGAR + FTC filings

Rare Disease deal benchmarks at a glance

Median deal terms for rare disease licensing transactions, by development phase. Data current as of 2026.

Phase	Median Upfront	Median Total Value	Median Royalty (Tiered)
Preclinical	$18M	$460M	4–8%
Phase 1	$45M	$780M	5–10%
Phase 2	$105M	$1.4B	7–14%
Phase 3	$290M	$3.1B	10–18%

Source: Ambrosia Benchmarker dataset, 1,900+ verified transactions (2017–2026). Primary sources: SEC EDGAR 8-K filings, FTC premerger notifications, ClinicalTrials.gov.

Recent comparable deals

Pfizer–Biohaven ($11.6B, migraine + rare neuro)
Novartis–The Medicines Company ($9.7B inclisiran)
BioMarin–Roctavian (gene therapy)

Why Rare Disease is priced this way

Rare disease consistently commands premium economics: orphan designation, accelerated review pathways, and high price-per-patient ($200K–$3M annual). M&A multiples often exceed in-licensing.

Rare Disease licensing — frequently asked

What is the median upfront payment for a Rare Disease licensing deal?

How are Rare Disease deal milestones structured?

What royalty rates are typical for Rare Disease licensing?

Is there a free Rare Disease deal calculator?

How does Rare Disease licensing compare to other therapeutic areas?

Rare disease consistently commands premium economics: orphan designation, accelerated review pathways, and high price-per-patient ($200K–$3M annual). M&A multiples often exceed in-licensing.